drugset / Trial / NCT01396265

Drug Interaction Study With Rifampicin and Afatinib

NCT01396265

Phase 1 Completed 22 enrolled Boehringer Ingelheim
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of the current study is to investigate the effect of the P-gp inducer rifampicin on the pharmacokinetics (PK) of afatinib in healthy male volunteers

Timeline

Start
2011-07
Primary completion
2011-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Afatinib Small molecule 40 mg Oral
Subject Rifampin Small molecule Oral

Indications

No indication recorded.